1-Aminomethyl-5-methoxyindane (AMMI) is a drug developed by a team led by David E. Nichols at Purdue University which acts as a selective serotonin releasing agent (SSRA) and binds to the serotonin transporter with similar affinity to DFMDA.
This page contains content from the copyrighted Wikipedia article "1-Aminomethyl-5-methoxyindane"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.